Headquartered in Boston, MA Fiscal year ends December NASDAQ: TNGX tangotx.com
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision cancer medicines. The company leverages the genetic principle of synthetic lethality to discover and develop therapies targeting critical vulnerabilities in cancer. Its lead program, vopimetostat, is an MTAP-selective once-daily PRMT5 inhibitor being developed as both a monotherapy and in combination with RAS(ON) inhibitors for MTAP-deleted cancers, including pancreatic cancer and lung cancer. Tango's pipeline also includes TNG456, which is in clinical trials for glioblastoma and other cancers. The company collaborates with Revolution Medicines on RAS(ON) inhibitor combinations and has initiated work with Erasca on additional combination studies. Tango trades on NASDAQ under the ticker TNGX and is transitioning from a research-led organization toward late-stage clinical development and commercialization readiness. Updated
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified…
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision cancer medicines. The company leverages the genetic principle of synthetic lethality to discover and develop therapies targeting critical vulnerabilities in cancer.
The Wall Street consensus 12-month price target for TNGX is $44.88.
